Remacemide is a low-affinity noncompetitive NMDA receptor antagonist with sodium channel blocking properties. It has been studied for a number of conditions including acute ischemic stroke, epilepsy, Parkinsons Disease, and Huntington's disease. It was concluded, that was unlikely that remacemide would be further developed as an antiepileptic drug. As for other conditions, there no any information in the literature, why remacemide is no longer being developed for them.

Dexsotalol is an isomer of antiarrhythmic drug d,l-sotalol, but in opposite to drug, it increases the incidence of arrhythmias

Demoxepam is a major pharmacologically active metabolite of the benzodiazepine chlordiazepoxide, the first drug within the class to gain approval by the Food and Drug Administration for use as an anticonvulsant, muscle relaxant and sedative hypnotic. Demoxepam has been shown to have antianxiety activity in man. The eventual elimination of demoxepam from the plasma was slow, with a range in half-life of 14-95 hr. The half-life of demoxepam was markedly longer than that of chlordiazepoxide. Demoxepam has an inhibitory effect on in vitro [3H]tryptophan binding to rat hepatic nuclei.

Chugai Pharmaceutical is developing a parathyroid 1 receptor agonist called as PCO371. It is known that parathyroid hormone (PTH) is essential for calcium homeostasis and its action is mediated by the PTH type 1 receptor. PCO371 can provide a new treatment option for PTH-related disorders, including hypoparathyroidism. This drug participated in phase I clinical trial in healthy volunteers. However, Chugai Pharmaceutical has terminated this study. No recent reports of the development of PCO371are available.

Xanthohumol is a prenylated flavonoid most abundant in hops. It is found in beers and refreshment drinks. It can attenuate several factors of the metabolic syndrome. It has been reported to inhibit adipogenesis or increase cell apoptosis and therefore can be used in preventing obesity. Xanthohumol inhibited angiogenesis by suppressing NF-κB activity in pancreatic cancer. Xanthohumol may represent a novel therapeutic agent for the management of pancreatic cancer. Moreover, it is in phase I clinical trials for preventing many types of cancer. It has a range of other biological properties: antiviral, antimalarial, antibacterial and as an osteoporosis preventing agent.

Ropitoin (TR2985) is a diphenylhydantoin derivative. It is an antiarrhythmic compound that causes a depression of the maximum upstroke velocity (used as a measure of cardiac function: an indirect index of the magnitude of the sodium current). Its effect was shown in several cardiac tissues and in guinea pig muscles and dog Purkinje fibers (myocardial cells). Ropitoin is believed to bind to the same receptor site in the sodium channel as mexiletine and quinidine. In an animal study, ropitoin was shown to be ineffective in preventing reentrant ventricular tachycardia (when the electric signal fails to die out after normal activation) or ventricular fibrillation. No information on the current use of this compound is available.

Cyprolidol is a pyridylcyclopropane derivative, developed by Neisler Laboratories. In animal models, cyprolidol produced an antidepressant effect qualitatively similar to those produced by imipramine. The compound blocked the tyramine-induced rise in blood pressure only in anesthetized dogs but potentiated it in conscious dogs. In man, cyprolidol was less effective than imipramine.

Trepipam is a benzazepine derivative. It is a D1-dopamine antagonist. Trepipam significantly reduced aggression in behaviorally disturbed adolescents and in acute schizophrenics without producing concomitant sedation. Trepipam specifically reduces aggressive and hyperactive behaviors in a wide range of laboratory tests in various species, without producing signs of overt CNS depression or neurological impairment. The drug is effective in reducing many forms of aggression including brain stimulated emotional behavior. Trepipam actually had little effect on gross behavior in mice or rats and only produced ataxia at lethal doses.